Incyte's Jakafi Demand Is Strong, Analyst Upgrades Stock [Yahoo! Finance]
Incyte Corporation (INCY)
Last incyte corporation earnings: 2/13 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
incyte.com/ir/investor-overview.aspx
Company Research
Source: Yahoo! Finance
Jakafi (ruxolitinib) net product revenues increased to $741.18 million, up 16% year over year, primarily due to a 10% increase in total demand. Guidance: Incyte forecasts 2024 Jakafi revenue of $2.74 billion—$2.77 billion, up from prior guidance of $2.71 billion—$2.75 billion. BofA Securities analyst upgraded Incyte's stock, citing strong demand for Jakafi li?ts overhang on competitive pressure in myelofibrosis and sees multiple shots on goal from the pipeline with several pivotal readouts expected in 2025. The analyst upgraded from Neutral to Buy with a price target of 90, up from $68 “We are also encouraged by continued growth for Opzelura with potential to expand into pediatric AD (approval expected in 2H25). We note 2025 will be a catalyst-rich year with several pivotal readouts,” the analyst added. Although clinical validation is still necessary, the BofA analyst writes that some of these programs may help offset the anticipated loss of exclusivity for Jakafi in 2028.
Show less
Read more
Impact Snapshot
Event Time:
INCY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
INCY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
INCY alerts
High impacting Incyte Corporation news events
Weekly update
A roundup of the hottest topics
INCY
News
- INCY ACTIVE INVESTIGATION: Contact Levi & Korsinsky if you lost money on your Incyte Corporation investmentAccesswire
- Incyte Co. (NASDAQ: INCY) was downgraded by analysts at StockNews.com from a "strong-buy" rating to a "buy" rating.MarketBeat
- Incyte Co. (NASDAQ: INCY) was downgraded by analysts at StockNews.com from a "strong-buy" rating to a "buy" rating.MarketBeat
- Lost Money on Incyte Corporation(INCY)? Contact Levi & Korsinsky Regarding an Ongoing InvestigationAccesswire
- Incyte Pauses Enrollment in Chronic Spontaneous Urticaria Study [Yahoo! Finance]Yahoo! Finance
INCY
Earnings
- 10/29/24 - Beat
INCY
Sec Filings
- 11/8/24 - Form SC
- 11/8/24 - Form 4
- 11/6/24 - Form 144
- INCY's page on the SEC website